(NASDAQ: SGMT) Sagimet Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Sagimet Biosciences's revenue in 2024 is $2,000,000.On average, 2 Wall Street analysts forecast SGMT's revenue for 2028 to be $2,303,703,933, with the lowest SGMT revenue forecast at $1,559,631,658, and the highest SGMT revenue forecast at $3,047,776,209. On average, 2 Wall Street analysts forecast SGMT's revenue for 2029 to be $7,530,719,915, with the lowest SGMT revenue forecast at $3,747,966,889, and the highest SGMT revenue forecast at $11,313,472,942.
In 2030, SGMT is forecast to generate $15,557,541,204 in revenue, with the lowest revenue forecast at $9,675,333,122 and the highest revenue forecast at $21,439,749,287.